近期,CAR-T疗法领域在全球和中国都取得了显著的临床进展和技术突破,在新的适应症获批、新一代技术平台(如双靶点、体内CAR-T)的初步验证等方面好消息不断。近日,锋寻生物对外公布信息,凭借自主研发的多维度优化体内CAR-T技术平台,已推动核心产品进入临床前关键阶段。其针对血液瘤的候选药物将于近期启动首次人体临床试验(IIT),有望打破传统CAR-T治疗局限,惠及更多患者。自成立以来,锋寻生物就...
Source Link近期,CAR-T疗法领域在全球和中国都取得了显著的临床进展和技术突破,在新的适应症获批、新一代技术平台(如双靶点、体内CAR-T)的初步验证等方面好消息不断。近日,锋寻生物对外公布信息,凭借自主研发的多维度优化体内CAR-T技术平台,已推动核心产品进入临床前关键阶段。其针对血液瘤的候选药物将于近期启动首次人体临床试验(IIT),有望打破传统CAR-T治疗局限,惠及更多患者。自成立以来,锋寻生物就...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.